Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

HK inno.N Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Amlodipine 5mg
Drug: Amlodipine 5mg, Candesartan cilexetil 16mg
Drug: Amlodipine 10mg, Candesartan cilexetil 16mg

First Posted Date: 2015-02-23

Last Posted Date: 2023-05-06

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 180

Registration Number: NCT02368665

Locations: 🇰🇷
Hallym University Sungsim Hospital, Anyang-si, Korea, Republic of
🇰🇷
Inje University Busan Baik Hospital, Busan, Korea, Republic of
🇰🇷
Inje University Haeundae Baik Hospital, Busan, Korea, Republic of

and more 16 locations

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Candesartan cilexetil 16mg
Drug: Amlodipine 10mg, Candesartan cilexetil 16mg

First Posted Date: 2015-02-23

Last Posted Date: 2023-05-06

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 181

Registration Number: NCT02368652

Locations: 🇰🇷
Hallym University Sungsim Hospital, Anyang-si, Korea, Republic of
🇰🇷
Inje University Busan Baik Hospital, Busan, Korea, Republic of
🇰🇷
Inje University Haeundae Baik Hospital, Busan, Korea, Republic of

and more 16 locations

Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor/Glucophage XR

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Atorvastatin 20mg and Metformin XR 500mg (Reference)
Drug: CJ-30056 20/500mg (Test)

First Posted Date: 2014-07-09

Last Posted Date: 2016-12-29

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 42

Registration Number: NCT02185066

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

Bioequivalence Study of CJ-30059

Phase 1

Conditions: Healthy Volunteers

Interventions: Drug: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)
Drug: CJ-30059 (Test)

First Posted Date: 2014-06-25

Last Posted Date: 2014-06-25

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 32

Registration Number: NCT02173912

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

The Food Effect on Pharmacokinetics and Safety of Fixed-dose Combination of CJ-30056 in Healthy Male Subjects

Phase 1

Completed

Conditions: Food Effect Study of CJ-30056 20mg/500mg

First Posted Date: 2014-06-11

Last Posted Date: 2016-12-29

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 28

Registration Number: NCT02160743

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CJ-40002

First Posted Date: 2014-05-26

Last Posted Date: 2016-12-29

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 40

Registration Number: NCT02146625

Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia
Schizophreniform Disorder
Schizoaffective Disorder

Interventions: Drug: A-prexa
Drug: Zyprexa

First Posted Date: 2014-05-14

Last Posted Date: 2014-05-14

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 64

Registration Number: NCT02137993

Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: combination administration

First Posted Date: 2014-02-24

Last Posted Date: 2017-09-12

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 56

Registration Number: NCT02069821

Locations: 🇰🇷
Chungnam national university hospital, Daejeon, Jung-gu, Korea, Republic of

A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

Phase 2

Conditions: Essential Hypertension

Interventions: Drug: Amlodipine 5mg
Drug: Amlodipine 10mg
Drug: Candesartan Cilexetil 8mg
Drug: Candesartan cilexetil 16mg

First Posted Date: 2014-02-11

Last Posted Date: 2014-04-30

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 384

Registration Number: NCT02059616

Locations: 🇰🇷
Seoul National University Bundang Hospital, Bundang, Korea, Republic of
🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of

and more 17 locations

Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.

First Posted Date: 2014-02-11

Last Posted Date: 2016-12-29

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 57

Registration Number: NCT02060019

Locations: 🇰🇷
Kyungpook university hospital, Deagu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy